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DrBACKGROUND Obesity and atrial ﬁbrillation (AF) frequently coexist. Weight loss reduces the burden of AF, but
whether this is sustained, has a dose effect, or is inﬂuenced by weight ﬂuctuation is unknown.
OBJECTIVES This study sought to evaluate the long-term impact of weight loss and weight ﬂuctuation on rhythm
control in obese individuals with AF.
METHODS Of 1,415 consecutive patients with AF, 825 had a body mass index $27 kg/m2 and were offered weight
management. After screening for exclusion criteria, 355 were included in this analysis. Weight loss was categorized as
group 1 ($10%), group 2 (3% to 9%), and group 3 (<3%). Weight trend and/or ﬂuctuation was determined by yearly
follow-up. We determined the impact on the AF severity scale and 7-day ambulatory monitoring.
RESULTS There were no differences in baseline characteristics or follow-up among the groups. AF burden and symptom
severity decreased more in group 1 compared with groups 2 and 3 (p < 0.001 for all). Arrhythmia-free survival with and
without rhythm control strategies was greatest in group 1 compared with groups 2 and 3 (p < 0.001 for both). In
multivariate analyses, weight loss and weight ﬂuctuation were independent predictors of outcomes (p < 0.001 for both).
Weight loss $10% resulted in a 6-fold (95% conﬁdence interval: 3.4 to 10.3; p < 0.001) greater probability of
arrhythmia-free survival compared with the other 2 groups. Weight ﬂuctuation >5% partially offset this beneﬁt, with a
2-fold (95% conﬁdence interval: 1.0 to 4.3; p ¼ 0.02) increased risk of arrhythmia recurrence.
CONCLUSIONS Long-term sustained weight loss is associated with signiﬁcant reduction of AF burden and maintenance
of sinus rhythm. (Long-Term Effect of Goal directed weight management on Atrial Fibrillation Cohort: A 5 Year follow-up
study [LEGACY Study]; ACTRN12614001123639) (J Am Coll Cardiol 2015;65:2159–69) © 2015 by the American College
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2160R ecent epidemiological data con-ﬁrmed the emergence of obesityand atrial ﬁbrillation (AF) as global
epidemics (1,2). In the United States, the
prevalence of obese individuals has risen
3-fold since 1960, with 1 in every 3 persons
being obese (3). If such trends continue un-
abated, it is estimated that 164 million
Americans will be obese by 2030, with an
additional health care cost of $66 billion
annually (4,5). The prevalence of AF is pro-
jected to reach 15.9 million in the United
States by 2050 (2,6,7). Because obesity isindependently associated with AF, these dual epi-
demics confer an enormous management and eco-
nomic burden (8–11).SEE PAGE 2170Obesity and its associated cardiometabolic como-
rbidities, such as hypertension, diabetes mellitus,
and sleep apnea have been proposed as contributors
to the expanding epidemic of AF (8,12,13), and are
thus potential targets for intervention to stem the
expanding AF epidemic. Weight loss in the short
term results in a reduction in the symptomatic AF
burden (14). Recent data demonstrated that aggres-
sive weight and risk factor management improves
maintenance of sinus rhythm after AF ablation (15).
Whether a critical weight loss threshold is re-
quired, or if beneﬁts conferred by the initial weight
loss are sustained in the long term is unknown.
Furthermore, obese individuals frequently oscillate
in weight over time, and the impact of such weight
ﬂuctuation on the arrhythmia burden is not known.
We hypothesized that weight loss, if sustained, will
be of incremental beneﬁt in rhythm control. In this
study, we assess the long-term impact of weight loss
and weight ﬂuctuation on rhythm control in obese
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STUDY POPULATION. The study included consecu-
tive patients who were referred for management of
symptomatic paroxysmal or persistent AF to the
Centre for Heart Rhythm Disorders at the University of
Adelaide, Adelaide, Australia. All patients with a body
mass index (BMI) $27 kg/m2 were included in this
analysis. Exclusion criteria were permanent AF, his-
tory of myocardial infarction or cardiac surgery in the
previous 12 months, signiﬁcant cardiac valvulopathy
or ventricular dysfunction, active malignancy, auto-
immune or systemic inﬂammatory diseases, severe
renal or hepatic failure, and <24 months of follow-up.
The study protocol was approved by the Hu-
man Research Ethics Committee of the Royal Ade-
laide Hospital and University of Adelaide, Adelaide,
Australia.
STUDY PROTOCOL AND DESIGN. All patients were
counseled on the importance of weight and risk factor
management, with optional participation in a dedi-
cated physician-led weight management clinic or
self-managed weight loss program.
Weight management . The weight and other risk
factor management protocols have been presented
previously and are outlined in the Online Appendix
(15). In brief, a structured motivational and goal-
directed program using face-to-face counseling was
used for weight reduction. Patients were reviewed
regularly (every 3 months in the initial phase), and
encouraged to use support counseling and schedule
more frequent reviews as required. Initial weight
reduction was attempted by a meal plan and behavior
modiﬁcation. Participants were required to maintain
a diet and physical activity diary. Meals consisted
of high protein and low glycemic index, calorie-
controlled foods. If patients lost <3% of weight after
3 months, they were then prescribed very-low-calorie
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2161New South Wales, Australia, or Nestle Health Science,
Vevey, Switzerland) for 1 to 2 meals/day. The initial
goal was to reduce body weight by 10%. After pa-
tients achieved the initial goal, meal replacement was
substituted to high protein and low glycemic index,
calorie-controlled foods to achieve a target BMI of
#25 kg/m2. Low-intensity exercise was prescribed
initially for 20 min thrice weekly and increasing to
at least 200 min of moderate-intensity activity per
week. Hypertension, glucose intolerance, sleep ap-
nea, alcohol, and tobacco use were screened for and
managed individually according to American Heart
Association/American College of Cardiology guide-
lines. Changes in metabolic (lipid proﬁle and fasting
insulin) and inﬂammatory state (high-sensitivity
C-reactive protein hsCRP) levels were monitored.
Weight loss deﬁni t ion . A stadiometer and digital
weighing machine were used to record height and
weight in light clothing without shoes, and BMI
was calculated. Anthropometric values measured at
annual follow-up were utilized for weight loss and
weight ﬂuctuation assessment. The American Heart
Association/American College of Cardiology guide-
lines recognize that any weight loss $3% is consid-
ered a meaningful reduction (16). To determine the
dose–response effect of weight loss on AF burden,
groups were divided as follows: $10% weight loss
(group 1), 3% to 9% weight loss (group 2), and <3%
weight loss or weight gain (group 3).
Weight trend deﬁni t ion . Weight trend was deter-
mined by percentage change in annual weight over
the course of the study. Linear weight loss was
deﬁned by continuous weight loss at each annual
follow-up with no interim weight gain of $1%. Linear
weight gain was deﬁned by continuous weight gain at
each annual follow-up with no interim weight loss
of $1%. Weight ﬂuctuation was deﬁned by $1%
weight cycle (“gain–loss” or “loss–gain”) between 2
consecutive annual follow-ups.
Quant iﬁcat ion of weight ﬂuctuat ion . To assess
the effect of the magnitude of weight ﬂuctuation, pa-
tients were divided on the basis of yearly follow-ups:
>5% weight ﬂuctuation (wide), 2% to 5% weight ﬂuc-
tuation (average), and<2%weight ﬂuctuation (stable).
Arrhythmia management . Management of AF was
undertaken in a dedicated AF clinic independent of
the weight management clinic. Usage of rate and
rhythm control strategies was at the treating physi-
cian’s discretion. The drugs used for rhythm control
included sotalol or ﬂecainide. Amiodarone was not
usually used. Ablation was advocated in patients who
remained symptomatic despite use of antiarrhythmic
drugs. The ablation technique used at our institutionwas previously described and is outlined in the
Online Appendix (17). AF was determined at least
annually by clinical review, 12-lead electrocardio-
gram, and 7-day Holter monitoring. In patients who
underwent ablation, procedural success was deter-
mined after a 3-month blanking period. AF was
considered any atrial arrhythmia $30 s. The earliest
date with documented AF was set as the date of
arrhythmia recurrence.
Cardiac structural parameters were monitored by
serial echocardiographic examinations. All echocar-
diographic and rhythm evaluations are detailed in the
Online Appendix and performed by operators blinded
to the patient’s weight management regimen.
OUTCOMES. The primary outcome was AF burden as
determined by symptom burden and AF freedom. AF
symptom burden was determined by the AF Severity
Scale (AFSS) (University of Toronto, Toronto, Ontario,
Canada), which quantitates 3 domains of AF-related
symptoms: frequency, duration, and severity (18).
The AFSS has been clinically validated and used for
assessment of AF burden (14,15). In addition, it pro-
vides a symptom subscale and global well-being
score. The AFSS questionnaire was administered at
baseline and ﬁnal follow-up. AF freedom was deter-
mined with 7-day Holter monitoring. Secondary out-
comes included structural parameters of left atrial
volume and left ventricular wall thickness from
echocardiographic studies.
Stat i s t i ca l ana lys is . Categorical variables are rep-
resented by frequencies and percentages. Continuous
variables are summarized by mean  SD. Differences
between the weight loss groups were assessed using
analysis of variance procedures for baseline charac-
teristics. A repeated measure analysis of variance was
used to assess change over time. For categorical var-
iables, change in status at follow-up was compared
between groups using a chi-square test. Time-to-
recurrence and event-free survival curves following
the last ablation procedure were estimated by the
Kaplan-Meier product-limit method. Differences be-
tween curves were tested with the log-rank test.
Predictors of recurrent AF were assessed using pro-
portional hazards Cox regression models. Candidate
variables with p < 0.1 in univariate analyses were
considered in multivariate regression models. Two-
tailed p < 0.05 was considered statistically signiﬁ-
cant. Statistical analysis was performed with SPSS
version 21.0 (SPSS, Inc., Chicago, Illinois).
RESULTS
BASELINE CHARACTERISTICS. Of 1,415 consecutive
patients with symptomatic AF, 825 patients had a BMI
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the ﬁnal cohort consisted of 355 patients (Figure 1):
135 in group 1 ($10% weight loss), 103 in group 2 (3%
to 9% weight loss), and 117 in group 3 (<3% weight-
loss). Baseline characteristics and follow-up dura-
tion (48.4  18.2, 46.0  16.7, and 48.3  18.4 months,
respectively; p ¼ 0.3) were similar for all groups
(Table 1).
WEIGHT LOSS AND MAINTENANCE. Weight change
was greater in group 1 than in groups 2 and 3 (–16.0 
3.0 kg vs. –6.0  0.4 kg vs. þ2.0  1.0 kg, respectively;
p < 0.001). This corresponded with higher participa-
tion in the dedicated weight management clinic (84%
in group 1 vs. 57% in group 2 vs. 30% in group 3; p <
0.001). The weight loss was largely durable over time
with 66% (34 of 52 patients) who lost $10% body
weight in the ﬁrst year maintaining their weight loss
at 34.5  15.5 months. Importantly, 85% of theseFIGURE 1 Patient Selection
Assessed for E
N=1,41
Patients with 
N=825
Final Coh
N=355
Total Weight at Final
Follow-Up
<3%WL or
WG
N=117
3-9%WL
N=103
≥10%WL
N=135
Flow diagram demonstrating patient recruitment and attrition. AF ¼ atr
Dx ¼ diagnosis; WF ¼ weight ﬂuctuation; WG ¼ weight gain; WL ¼ weipatients attended the weight management clinic (p <
0.001). In contrast, only 2 of the 18 patients who had
regained weight after initial weight loss of $10%
in the ﬁrst year attended the weight management
clinic.
EFFECT OF WEIGHT LOSS ON RISK FACTOR
PROFILE. Table 2 shows the impact of weight man-
agement on various cardiac risk factors.
Blood pressure contro l . There was a stepwise
improvement in mean systolic blood pressure (BP)
with weight loss (18.0  5.0 mm Hg vs. 10.0  3.0
mm Hg vs. 7.0  2.0 mm Hg for groups 1, 2, and 3
respectively; p < 0.001). This was despite reduced,
unchanged, and increased antihypertensive agent use
in groups 1, 2, and 3, respectively (p ¼ 0.037).
L ip id management . A greater reduction in low-
density cholesterol, triglycerides, and total choles-
terol levels was seen in group 1 compared with groupsligibility
5
Met Exclusion Criteria (N=293)
Terminal Cancer (N=10)
Inflammatory Dx (N=20)
Permanent AF (N=84)
AV Node ablation (N=12)
AF ablation (N=90)
Severe Medical Illness (N=77)
Patients from other states (N=177)
BMI ≥27
ort
Yearly Weight Trend
Linear
Weight Loss
N=141
Weight
Fluctuation
N=179
No Loss or
Linear Gain
N=24
<2%WF
N=54
2-5%WF
N=68
>5%WF
N=57
ial ﬁbrillation; AV ¼ aortic valve; BMI ¼ body mass index;
ght loss.
TABLE 1 Baseline Characteristics
$10%
WL Group 1
(N ¼ 135)
3%–9% WL
Group 2
(N ¼ 103)
<3% WL
Group 3
(N ¼ 117)
p
Value
Age, yrs 65  11 63  11 61  11 0.06
Male 86 (64) 65 (63) 83 (71) 0.37
WL clinic attendance 114 (84) 59 (57) 35 (30) <0.001
Anthropometric measures and blood pressure
Weight, kg 101.3  17.0 98.7  16.4 100.2  16.8 0.52
BMI, kg/m2 33.6  4.7 32.7  4.4 32.9  4.8 0.24
SBP, mm Hg 147  17 144  17 146  17 0.33
Atrial ﬁbrillation
Paroxysmal 71 (53) 57 (55) 60 (52) 0.86
Nonparoxysmal 64 (47) 46 (45) 45 (56)
Metabolic risk factors
Hypertension 109 (81) 75 (73) 90 (78) 0.30
DM 41 (30) 28 (27) 34 (29) 0.35
IGT 18 (13) 8 (8) 8 (7)
Hyperlipidemia 66 (49) 45 (44) 56 (48) 0.70
Coronary artery disease 21 (16) 12 (12) 11 (9) 0.31
Valvulopathy 8 (6) 3 (3) 8 (7) 0.41
AHI >30 69 (51) 52 (50) 61 (52) 0.97
Alcohol excess (>30 g/week) 42 (31) 35 (34) 34 (29) 0.73
Smoker 50 (37) 41 (40) 47 (40) 0.86
Medication use
Antiarrhythmic 1.1  0.7 1.0  0.7 0.9  0.8 0.10
Antihypertensive 1.0  0.9 1.0  0.8 1.1  1.0 0.08
Serology and lipid proﬁle
hsCRP, mg/l 5.1  9.2 4.4  5.8 4.1  2.9 0.70
Fasting insulin level, mU/l 18.1  6.7 16.6  6.3 18.1  7.0 0.10
LDL level, mg/l 112  38 116  35 104  35 0.20
HDL level, mg/l 46  15 46  15 42  12 0.11
TG level, mg/l 141  62 141  53 141  62 0.78
Total cholesterol, mg/l 189  37 185  42 181  42 0.50
Echocardiographic measures
LA volume indexed, mls/m2 37.6  5.4 38.5  6.2 39.0  3.8 0.20
LV IVS, mm 11.7  2.0 11.5  2.0 11.5  2.0 0.24
LVEDD, cm 5.0  0.6 5.0  0.6 5.0  0.6 0.92
E/E’ ratio 12.7  4.2 12.0  4.6 11.3  3.7 0.06
Atrial Fibrillation Severity Scale
Frequency (1–10) 7.0  1.6 7.0  1.3 7.0  1.7 0.97
Duration (1–10) 7.1  1.8 6.7  1.8 6.9  1.7 0.21
Severity (1–10) 7.0  1.9 7.1  1.5 6.8  1.5 0.50
Symptom (0–35) 19.0  5.9 18.1  4.9 17.7  5.6 0.19
Global well-being (1–10) 2.7  0.8 2.4  0.9 2.5  0.9 0.4
Values are mean  SD or n (%).
AHI ¼ apnea–hypopnea index; BMI ¼ body mass index; DM ¼ diabetes mellitus; HDL ¼ high-density
lipoprotein; hsCRP ¼ high-sensitive C-reactive protein; IGT ¼ impaired glucose tolerance; LA ¼ left atrium;
LDL ¼ low-density lipoprotein; LVEDD ¼ left ventricular end-diastolic diameter; LV IVS ¼ left ventricular
interventricular septum; SBP ¼ systolic blood pressure; TG ¼ triglyceride; WL¼ weight loss.
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lipid-lowering therapy (p ¼ 0.04).
Glycemic contro l . Diabetic patients demonstrated
improved glycemic control (glycosylated hemoglobin
<7%) from group 3 to group 2 to group 1 (p < 0.001).
This was in conjunction with a decrease in fasting
insulin in group 1 (p < 0.001) and group 2 (p ¼ 0.06)
as opposed to an increased insulin level in group 3
(p ¼ 0.03).
Inﬂammat ion . Patients in groups 1 and 2 demon-
strated a decrease in mean hsCRP (p < 0.001 and p ¼
0.004, respectively) as opposed to increased hsCRP
levels in group 3 (p ¼ 0.001).
EFFECT OF WEIGHT LOSS ON CARDIAC STRUCTURE.
Table 2 shows the effect of weight loss on cardiac
structure. Left atrial volume indexed for body surface
area decreased signiﬁcantly with weight loss in group 1
(p < 0.001) and group 2 (p < 0.001), yet increased in
group 3 (p ¼ 0.02). Likewise, interventricular septal
(IVS) thickness decreased signiﬁcantly with weight
loss in both group 1 (p ¼ 0.001) and group 2 (p ¼ 0.03),
but remainedunchanged in group 3 (p¼0.33). A similar
trend was seen in left ventricular end-diastolic diam-
eter and E/E0 for group 1 and group 2, with subjects in
group 3 showing an increasing E/E0 (p ¼ 0.001).
EFFECT OF WEIGHT LOSS ON ATRIAL FIBRILLATION
SYMPTOM BURDEN. AF frequency, duration, symp-
toms, and symptom severity were improved in groups
1 and 2 compared with group 3 (p < 0.001) (Table 2).
The global well-being score improved by 5.9  0.9
in group 1 and was higher than in groups 2 and 3
(p < 0.001).
Freedom from AF without the use of rhythm
control s t rateg ies . Figure 2A demonstrates the
“ablation and drug free” AF freedom. At ﬁnal follow-
up, 45.5% of group 1, 22.2% of group 2, and 13.4% of
group 3 (p < 0.001) remained free from arrhythmia
without antiarrhythmic drugs or ablation. Univariate
predictors of AF recurrence were the following: group
2 ([compared to group 1]: hazard ratio [HR]: 1.8; 95%
conﬁdence interval [CI]: 1.3 to 2.5); group 3 ([compared
to group 1]: HR: 2.1; 95% CI: 1.6 to 3.0; p < 0.001);
interventricular septal thickness (HR: 0.44; 95% CI:
0.23 to 0.86; p ¼ 0.01); and E/E0 ratio (HR: 1.4; 95% CI:
1.2 to 1.7; p < 0.001). On multivariate analysis, group 2
(compared to group 1): HR: 2.0; 95% CI: 1.4 to 2.9, and
group 3 (compared to group 1): HR: 3.0; 95% CI: 2.0 to
4.3; p < 0.001), IVS (HR: 0.2; 95% CI: 1.1 to 2.1;
p < 0.001), and E/E0 ratio (HR: 1.5; 95% CI: 1.2 to 1.9;
p < 0.001) remained independent predictors of AF
recurrence.
Tota l ar rhythmia- f ree surv iva l . Figure 2B dem-
onstrates the total arrhythmia-free survival withsigniﬁcant attrition in group 3 compared with groups
1 and 2. At ﬁnal follow-up, total arrhythmia-free
survival rates were 86.2% in group 1 compared with
65.5% in group 2 and 39.6% in group 3 (p < 0.001).
There were no differences in the mean number of
ablation procedures among the 3 groups (p ¼ 0.8). At
ﬁnal follow-up, the mean number of antiarrhythmic
TABLE 2 Weight Loss
$10% WL Group (N ¼ 135) 3%–9% WL Group (N ¼ 103) < 3% WL Group (N ¼ 117)
p Value†Baseline Follow-Up‡ p Value* Baseline Follow-Up‡ p Value* Baseline Follow-Up‡ p Value*
Weight, kg 101  17 85  14 <0.001 99  16 93  16 <0.001 100  17 102  18 <0.001 <0.001
BMI, kg/m2 33.7  4.7 28.4  4.0 <0.001 32.7  4.4 30.8  4.2 <0.001 33.0  4.9 33.5  5.3 <0.001 <0.001
Mean SBP, mm Hg 147  17 129  12 <0.001 144  17 134  14 <0.001 146 17 139  15 <0.001 <0.001
DM with HbA1c $7 40 (30) 5 (4) — 28 (27) 15 (15) — 34 (29) 23 (20) — <0.001
Medication use
Anti-HTN 1.0  0.9 0.5  0.6 <0.001 0.7  0.8 0.7  0.6 0.74 0.8  1.0 1.0  0.7 0.01 <0.001
On lipid Rx 66 (49) 37 (27) — 45 (44) 38 (37) — 56 (48) 54 (46) — <0.001
AAD 1.1  0.7 0.1  0.4 <0.001 1.0  0.7 0.5  0.6 <0.001 0.8  0.8 0.4  0.6 <0.001 <0.001
Serology and lipid proﬁle
hsCRP, mg/l 5.1  9.2 1.2  2.4 <0.001 4.4  5.8 2.7  3.2 0.004 4.1  2.9 4.9  5.0 0.001 <0.001
Fasting insulin, mU/l 18.3  6.6 8.4  3.9 <0.001 16.9  6.1 14.8  9.4 0.06 14.5  6.9 17.3  9.6 0.03 <0.001
LDL level, mg/dl 116  37 89  31 <0.001 116  35 93  23 <0.001 104  35 108  31 0.05 <0.001
HDL level, mg/dl 50  15 58  15 <0.001 46  11 50  11 0.01 42  11 46  11 0.79 <0.001
TG level, mg/dl 141  62 97  35 <0.001 141  53 115  53 <0.001 141  62 159  62 0.03 <0.001
Total cholesterol, mg/dl 189  38 158  35 <0.001 185  42 162  27 <0.001 178  42 178  35 0.51 <0.001
Echocardiogram
Indexed LA volume, ml/m2 37.6  5.4 30.9  6.4 <0.001 39.5  6.2 34.7  10.0 <0.001 39.0  3.8 40.4  5.9 0.02 <0.001
IV septum, mm 11.7  2.0 10.1  0.7 0.001 11.5  2.0 10.9  2.0 0.03 11.5  2.0 11.4  2.0 0.33 <0.001
LVEDD, cm 5.0  0.6 4.6  0.9 <0.001 5.0  0.6 4.9  0.7 0.01 5.0  0.6 5.0  0.6 0.82 <0.001
E/E’ ratio 12.8  4.2 8.5  3.3 <0.001 11.9  4.6 9.1  3.2 <0.001 11.6  3.5 13.7  5.4 0.001 <0.001
AF symptom score
AF frequency (1–10) 7.0  1.5 3.0  1.9 <0.001 7.0  1.3 3.7  1.7 <0.001 7.1  1.5 4.6  1.6 <0.001 <0.001
AF duration (1.25–10) 7.1  1.8 4.2  2.5 <0.001 6.7  1.8 4.9  2.4 <0.001 6.8  1.7 5.4  2.1 <0.001 <0.001
AF episode severity (1–10) 7.0  1.9 3.3  1.8 <0.001 7.1  1.4 4.3  2.0 <0.001 6.8  1.5 5.4  2.1 <0.001 <0.001
AF symptom subscale (0–35) 19.1  5.9 9.2  5.0 <0.001 18.1  4.9 11.1  4.9 <0.001 18.2  5.1 13.6  4.4 <0.001 <0.001
Global well-being (1–10) 2.7  0.8 8.1  1.2 <0.001 2.4  0.9 6.1  0.9 <0.001 2.5  0.9 5.7  2.0 0.001 <0.001
Values are mean  SD or n (%). Impact of weight loss on cardiac risk factors, cardiac structure, and atrial ﬁbrillation (AF) severity from baseline to follow-up. *p Value refers to within group difference
(baseline to follow-up). †p Value refers to between group differences over time (group–time interaction). ‡Median follow-up: 48.4  18.2 months for group 1, 46.0  16.7 months for group 2, and 48.3 
18.4 months for group 3.
AAD ¼ antiarrhythmic drug; HbA1c ¼ glycosylated hemoglobin; HTN ¼ hypertension; Rx ¼ prescription; other abbreviations as in Table 1.
Pathak et al. J A C C V O L . 6 5 , N O . 2 0 , 2 0 1 5
Weight Management and AF M A Y 2 6 , 2 0 1 5 : 2 1 5 9 – 6 9
2164drug use was signiﬁcantly lower in group 1 compared
with groups 2 and 3 (p < 0.001). Univariate pre-
dictors of AF recurrence were the following: group 2
([compared to group 1]: HR: 2.8; 95% CI: 1.5 to 5.2);
group 3 ([compared to group 1]: HR: 5.5; 95% CI: 3.1
to 9.6; p < 0.001); diabetes (HR: 1.6; 95% CI: 1.1 to
2.3; p ¼ 0.013); and current smoking status (HR: 1.4;
95% CI: 1.0 to 2.1; p ¼ 0.048). On multivariate anal-
ysis, group 2 ([compared to group 1]: HR: 3.1; 95% CI:
1.7 to 5.6; p < 0.001); group 3 ([compared to
group 1]: HR: 5.9; 95% CI: 3.4 to 10.3; p < 0.001) and
history of diabetes (HR: 1.8; 95% CI: 1.2 to 2.7;
p ¼ 0.002) remained independent predictors of AF
recurrence.
Effect of weight loss trend . Of 355 patients, 141
had linear weight loss, 24 had linear weight gain, and
179 had weight ﬂuctuation. Eleven patients were
excluded from analysis, due to missing yearly weight
data. Figure 3 demonstrates total arrhythmia-free
survival on the basis of weight change trends. Atﬁnal follow-up, 76% of patients with linear weight
loss remained free of arrhythmia (p < 0.001). Weight
ﬂuctuation offset some of the beneﬁt conferred by
weight loss, with 59% patients remaining free from
AF. However, this remained higher than the no
weight loss or weight gain group, where only 38%
remained free of AF (p < 0.001).
Effect of weight ﬂuctuat ion . Of 179 patients with
weight ﬂuctuation during the annual follow-ups, 54
had #2%, 68 had 2% to 5%, and 57 had >5% weight
ﬂuctuation. Patients attending the dedicated weight
management clinic had smaller weight ﬂuctuation:
69% of the <2% group, 55% of the 2% to 5% group, and
30% of the >5% weight ﬂuctuation group (p < 0.001).
Table 3 shows the impact of weight ﬂuctuation
on various cardiometabolic risk factors. More than
5% weight ﬂuctuation was associated with signiﬁ-
cantly increased requirement of antihypertensive
medication (p ¼ 0.04). Signiﬁcantly lower systolic BP
was seen in patients with <2% weight ﬂuctuation
FIGURE 2 Atrial Fibrillation Freedom Outcome According to Group
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(A) Kaplan-Meier curve for AF-free survival without the use of rhythm control strategies. (B) Kaplan-Meier curve for AF-free survival for total AF-free survival (multiple
ablation procedures with and without drugs). Abbreviations as in Figure 1.
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2165compared with 2% to 5% weight ﬂuctuation and >5%
weight ﬂuctuation groups. Mean fasting insulin
(p ¼ 0.01), hsCRP level (p ¼ 0.05), and serum low-
density lipoprotein cholesterol (p < 0.001) levels
were signiﬁcantly higher in patients with >5% weight
ﬂuctuation. Similarly, >5% weight ﬂuctuation was
associated with an adverse impact on cardiac struc-
tural remodeling, with left atrial volume indexed
for body surface area, IVS, and left ventricular
end-diastolic diameter remaining largely unchanged
compared with patients with <5% weight ﬂuctuation.
Figure 3 shows total arrhythmia-free survival on
the basis of degree of weight ﬂuctuation, with signif-
icant attrition seen with >5% compared with #5%
weight ﬂuctuation. At ﬁnal follow-up, 85.2% of pa-
tients with<2%weight ﬂuctuation, 59%with 2% to 5%
weight ﬂuctuation, and 44% with >5% (p < 0.001)
remained arrhythmia free. After adjustment for base-
line BMI, the effect of weight ﬂuctuation remained
statistically signiﬁcant for total AF recurrence
(p ¼ 0.03). On multivariate analysis, >5% weight
ﬂuctuation was associated with an increased risk of
AF recurrence compared with <2% weight ﬂuctuation
(HR: 2.06, 95% CI: 1.0 to 4.3; p ¼ 0.02).DISCUSSION
This study demonstrates that in overweight and
obese individuals with symptomatic AF, progressive
weight loss has a dose-dependent effect on long-
term freedom from AF (Central Illustration). Long-
term weight loss maintenance is achievable in
these patients and is associated with a 6-fold
greater freedom from AF. Notably, weight ﬂuctua-
tion of >5% had an adverse effect on overall
freedom from AF, with a 2-fold greater likelihood
of recurrent arrhythmia. Weight loss was also as-
sociated with beneﬁcial structural remodeling,
including signiﬁcant reductions in left atrial vol-
umes and left ventricular hypertrophy. Importantly,
achieving and maintaining weight loss was facili-
tated by a dedicated physician-led clinic that was
focused on the management of weight and risk
factors. These ﬁndings underscore the importance
of treating underlying causative conditions when
attempting to maintain sinus rhythm in obese AF
patients.
Epidemiological data have shown an incremental
risk of AF with a progressive increase in BMI (8).
TABLE 3 Weight Fluctuation
<2% WF Group (N ¼ 54) 2%–5% WF Group (N ¼ 68) > 5%WF Group (N ¼ 57)
p Value†Baseline Follow-Up‡ p Value* Baseline Follow-Up‡ p Value* Baseline Follow-Up‡ p Value*
BMI, kg/m2 32.6  4.7 29.2  4.8 <0.001 33.3  3.9 30.9  4.5 <0.001 32.3  4.0 31.8  4.8 0.10 <0.001
Mean SBP, mm Hg 147  21 130  14 <0.001 146  17 132  13 <0.001 146  16 140  14 0.01 0.002
DM with HbA1c $7 16 (29) 4 (7) — 18 (26) 9 (13) — 14 (25) 6 (11) — 0.056
Medication use
Anti-HTN 1.0  0.8 0.6  0.6 0.04 1.0  0.9 0.6  0.5 0.01 0.9  1.1 0.9  0.7 1.00 0.037
On lipid Rx 27 (50) 19 (35) — 29 (43) 21 (31) — 32 (56) 33 (57) — 0.04
AA 1.0  0.8 0.4  0.6 <0.001 1.2  0.7 0.3  0.5 <0.001 0.9  0.7 0.3  0.5 <0.001 0.21
Serology and lipid proﬁle
hsCRP, mg/l 3.4  3.5 1.6  2.3 0.001 5.5  11.6 2.8  3.8 0.05 3.3  6.1 4.4  5.7 0.35 0.05
Fasting insulin level, mU/l 17.7  7.7 12.5  9.5 0.08 17.4  5.6 12.5  10.0 0.001 12.3  5.8 14.5  8.9 0.23 0.01
LDL level, mg/dl 108  31 89  23 <0.001 116  35 92  27 <0.001 104  35 112  31 0.12 <0.001
HDL level, mg/dl 46  11 54  15 <0.001 46  15 54  15 <0.001 46  11 46  15 0.39 0.01
TG level, mg/dl 133  53 106  44 <0.001 141  53 115  53 0.003 141  80 141  71 0.91 0.02
Total cholesterol, mg/dl 185  35 162  31 <0.001 189  35 162  31 <0.001 178  46 174  35 0.21 0.02
Echocardiogram
Indexed LA volume, ml/m2 37.4  4.9 32.2  7.2 <0.001 38.4  4.3 33.8  8.0 <0.001 39.2  4.2 39.8  6.5 0.55 <0.001
IV septum, mm 12.0  2.0 11.1  1.2 <0.001 11.5  2.0 11.0  2.0 0.01 11.4  2.0 11.2  2.0 0.59 0.04
LVEDD, cm 4.9  0.6 4.7  0.7 0.05 4.9  0.5 4.7  0.7 0.05 5.0  0.6 5.0  0.6 0.71 0.13
Lateral E/E’ ratio 11.9  3.5 9.4  3.8 <0.001 12.5  4.0 10.4  4.8 0.01 12.1  3.9 12.7  5.2 0.42 0.005
Values are mean  SD or n (%). Impact of weight ﬂuctuation on cardiac risk factors and cardiac structure from baseline to follow-up. *p Value refers to within group difference (baseline to follow-up).
†p Value refers to between group differences over time (group–time interaction). ‡Median follow-up: 48.4  18.2 months for group 1, 46.0  16.7 months for group 2, and 48.3  18.4 months for group 3.
WF ¼ weight ﬂuctuation; other abbreviations as in Tables 1 and 2.
FIGURE 3 Outcomes of Atrial Fibrillation Freedom According to Weight Trend and Weight Fluctuation
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(A) Kaplan-Meier curve for total AF-free survival (multiple ablation procedures with and without drugs) according to weight trend. (B) Kaplan-Meier curve for total
AF-free survival (multiple ablation procedures with and without drugs) according to weight ﬂuctuation. Abbreviations as in Figure 1.
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CENTRAL ILLUSTRATION Weight Management and Atrial Fibrillation
Pathak, R.K. et al. J Am Coll Cardiol. 2015; 65(20):2159–69.
(Left) Obesity is associated with a variety of associated comorbidities. These are all associated with progression of the atrial substrate and the development of atrial
ﬁbrillation (AF). (Top) A dedicated weight management program with weight loss (WL) is associated with reverse remodeling of the atrial substrate and a dose-
dependent reduction in the AF burden, which is sustained in the long term. (Bottom) The consequence of weight ﬂuctuation, which somewhat curtails the beneﬁcial
effects of WL.
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2167Obesity is associated with structural and electrical
remodeling of the atria that forms the substrate in the
development and progression of AF (19,20). Weight
loss results in reversal of atrial dilation and left ven-
tricular hypertrophy, as well as a marked reduction of
AF symptoms and arrhythmia burden (14). However,
controversies exist regarding the long-term sus-
tainability of weight loss (21). In the present study,
progressive and linear weight loss of $10% was
associated with marked improvement in long-term
freedom from AF. Previously symptomatic AF pa-
tients (45.5%) no longer required antiarrhythmic
medications or ablation. In this study, 66% of the
patients who lost $10% weight maintained the weight
loss at long-term follow-up. Notably, participation in
a dedicated weight management clinic was associated
with higher weight loss maintenance. These results
highlight the central role of a dedicated weight
management clinic in treating overweight and obese
patients with AF.
Our data provided a unique opportunity to ascer-
tain the effect of weight ﬂuctuation during the weight
loss process. Our results revealed that >5% weight
ﬂuctuation lessened the beneﬁt conferred by weightloss. This effect of weight ﬂuctuation on AF recur-
rence risk remained signiﬁcant despite adjusting for
baseline weight, and was in accord with previous
studies that showed that weight ﬂuctuation was
associated with an increased risk of hypertension and
diabetes, as well as an increase in other cardio-
metabolic traits (22–25). Weight ﬂuctuation occurred
signiﬁcantly less often in patients who regularly
attended the dedicated weight management clinic.
Patient engagement and collaborative involvement
improved treatment plan adherence and persistence,
and might be “the forgotten piece” in the compliance
puzzle.
It is probable that multiple mechanisms contrib-
uted to the impact of weight loss on reduction of AF
burden. Obesity clusters with other cardiovascular
risk factors, including impaired glucose tolerance,
dyslipidemia, hypertension, and sleep apnea (26,27),
which are all associated with an increased AF risk in
the general population (12,13,28). Intentional weight
loss in obese patients systematically reduces these
allied risk factors (29–33). In this study, we observed
the beneﬁcial effects of weight loss on BP, diabetic
control, the lipid proﬁle, and inﬂammation, all of
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Weight loss is associated with a reduction in the
burden and symptomatic severity of AF, but weight
ﬂuctuations >5% have an adverse effect that is
associated with a greater likelihood of recurrent AF.
COMPETENCY IN PATIENT CARE: A physician-led
clinic focused on engaging patients in management of
excess body weight and related cardiovascular risk
factors promotes sustained weight loss, reduces
weight ﬂuctuations, and is associated with greater
long-term freedom from recurrent AF.
TRANSLATIONAL OUTLOOK: Additional studies
are needed to determine whether weight loss pro-
grams and/or procedures in susceptible individuals
could prevent or delay the onset of AF, ameliorate the
associated atrial pathology, and avoid or reduce the
need for anticoagulation to prevent stroke.
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2168which might have contributed to reduction of the AF
burden. Our previous work demonstrated that short-
term weight loss and other risk factor management
resulted in a reduction of the AF burden (14,15). The
present study demonstrated that these beneﬁcial
effects on AF burden persisted during long-term
follow up, were dose-dependent, but were also
partially offset in the face of signiﬁcant weight
ﬂuctuation.
STUDY LIMITATIONS. This study has the potential for
bias inherent to observational studies. However,
measurement bias was reduced through standardized
processes in our clinic, and the evaluation by opera-
tors was blinded to the patient’s weight management
regimen. AF burden assessment using 7-day Holter
monitoring might miss some AF episodes. However,
this was utilized for AF freedom assessment in
both the groups and was a limitation for all groups.
Ascertainment bias was reduced through the routine
collection of outcome data. Importantly, the impact
of weight ﬂuctuation on AF burden could not be
evaluated by a randomized design. Finally, weight
loss resulted in improvement in various associated
risk factors, such as sleep apnea and BP. This study
did not provide insight into the relative contribution
of each risk factor.
CONCLUSIONS
Sustained weight loss, particularly with avoidance
of weight ﬂuctuation, is associated with a dose-
dependent reduction in AF burden and maintenance
of sinus rhythm. This occurs in conjunction withfavorable changes in the cardiometabolic risk factor
proﬁle, inﬂammatory state, and cardiac remodeling.
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